Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001179110-17-008246
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2017-05-31 15:31:53
Reporting Period:
2017-05-25
Filing Date:
2017-05-31
Accepted Time:
2017-05-31 15:31:53
Original Submission Date:
2017-05-26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1371217 Enteromedics Inc ETRM () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1110780 Carl Goldfischer 2800 Patton Road
St. Paul MN 55113
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-05-25 4,571 $4.85 0 No 4 S Indirect See footnote.
Common Stock Disposition 2017-05-25 97 $4.85 0 No 4 S Indirect See footnote.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote.
No 4 S Indirect See footnote.
Footnotes
  1. The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.
  2. This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired.
  3. Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
  4. Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.